Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Ali N. Chamseddine"'
Autor:
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag‐Miliani, Clémence Henon, Cécile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honoré, Axel Le Cesne, Olivier Mir
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3160-3166 (2023)
Abstract Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single‐agent in a larger series of patients with advanced angiosarcoma. We retrospectivel
Externí odkaz:
https://doaj.org/article/778e03d4ac564846b7db152411c47d9f
Autor:
Sarah Watson, Benjamin Verret, Stanislas Ropert, Julien Adam, Rastislav Bahleda, Sylvain Briand, Andrea Cavalcanti, Ali N. Chamseddine, Charles Court, Elie Fadel, Matthieu Faron, Leila Haddag‐Miliani, Clémence Henon, Cécile Le Pechoux, Antonin Levy, Olaf Mercier, Carine Ngo, Charles Honoré, Axel Le Cesne, Olivier Mir
Publikováno v:
Cancer Medicine. 12:3160-3166
Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed
Autor:
Axel Le Cesne, Julien Adam, Etienne Rouleau, Carine Ngo, Anaïs Brunet, Arnaud Bayle, Olaf Mercier, Elie Fadel, Sylvain Briand, Charles Court, Antonin Levy, Cécile Le Péchoux, Leila Haddag-Miliani, Françoise Rimareix, Matthieu Faron, Andrea Cavalcanti, Sarah N. Dumont, Julien Dômont, Ali N. Chamseddine, Charles Honoré, Olivier Mir
Supplementary tables 1-3 and supplementary figures 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c8339b6f7124ec3ad5243ff2163f33
https://doi.org/10.1158/1078-0432.22477694
https://doi.org/10.1158/1078-0432.22477694
Autor:
Axel Le Cesne, Julien Adam, Etienne Rouleau, Carine Ngo, Anaïs Brunet, Arnaud Bayle, Olaf Mercier, Elie Fadel, Sylvain Briand, Charles Court, Antonin Levy, Cécile Le Péchoux, Leila Haddag-Miliani, Françoise Rimareix, Matthieu Faron, Andrea Cavalcanti, Sarah N. Dumont, Julien Dômont, Ali N. Chamseddine, Charles Honoré, Olivier Mir
Purpose:Desmoid-type fibromatosis (DF) are locally aggressive neoplasms, with a need for effective systemic treatment in case of progression to avoid the short- and long-term complications of local treatments.Experimental Design:We retrospectively an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cda734c7902a337548ff574e2cb65e1
https://doi.org/10.1158/1078-0432.c.6529739.v1
https://doi.org/10.1158/1078-0432.c.6529739.v1
Autor:
Françoise Rimareix, Olivier Mir, Leila Haddag-Miliani, Etienne Rouleau, Charles Honoré, Olaf Mercier, Carine Ngo, Anaïs Brunet, Andrea Cavalcanti, Charles Court, Sarah Dumont, Sylvain Briand, Axel Le Cesne, Cécile Le Péchoux, Julien Domont, Antonin Levy, Elie Fadel, Julien Adam, Ali N. Chamseddine, Matthieu Faron, Arnaud Bayle
Publikováno v:
Clinical Cancer Research. 26:6277-6283
Purpose: Desmoid-type fibromatosis (DF) are locally aggressive neoplasms, with a need for effective systemic treatment in case of progression to avoid the short- and long-term complications of local treatments. Experimental Design: We retrospectively
Publikováno v:
Pharmacologytherapeutics. 231
Tumor-associated macrophages (TAM) plasticity and diversity are both essential hallmarks of the monocyte-macrophage lineage and the tumor-derived inflammation. TAM exemplify the perfect adaptable cell with dynamic phenotypic modifications that reflec
Autor:
Jean-Pierre Armand, Tuvana Satar, Angelo Paci, Ali N. Chamseddine, Xavier Paoletti, Olivier Mir, Michel Ducreux
Publikováno v:
Pharmacology and Therapeutics
Pharmacology and Therapeutics, Elsevier, 2019, 199, pp.1-15. ⟨10.1016/j.pharmthera.2019.03.002⟩
Pharmacology and Therapeutics, Elsevier, 2019, 199, pp.1-15. ⟨10.1016/j.pharmthera.2019.03.002⟩
Irinotecan is an anticancer drug with a broad spectrum of activity, characterized by multistep and complex pharmacology. Regardless of its schedule of administration, neutropenia and delayed-type diarrhea are the most common side effects. The latter
Autor:
Justine Gantzer, Maud Toulmonde, François Severac, Ali N. Chamseddine, Céline Charon-Barra, Agathe Bourgmayer, Francois Bertucci, Thomas Ryckewaert, Thibaud Valentin, Nelly Firmin, Loic Chaigneau, Emmanuelle Bompas, Philippe Follana, Nathalie Rioux-Leclercq, Laurence Bozec Lemoal, Florence Duffaud, Patrick Schöffski, Jean-Yves Blay, Mehdi Brahmi, Gabriel G. Malouf
Publikováno v:
Journal of Clinical Oncology. 40:11571-11571
11571 Background: Perivascular Epithelioid Cell Neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. The current understanding of their natural history is limited. Previously described clinicopathological factors aimed to defin
Autor:
Xavier Paoletti, Koji Oba, Olivier Bouché, Ali N. Chamseddine, Narikazu Boku, A. Auperin, Tuvana Satar, Marc Buyse
Publikováno v:
Contemporary Clinical Trials
Contemporary Clinical Trials, Elsevier, 2021, 105, ⟨10.1016/j.cct.2021.106400⟩
Contemporary Clinical Trials, Elsevier, 2021, 105, ⟨10.1016/j.cct.2021.106400⟩
Background and objectives: The net treatment effect ( increment ) is a new method to assess the treatment benefit that combines multiple time-to-event, binary and continuous endpoints according to a pre-specified sequence. It represents the net proba
Autor:
Stéphane Terry, Amirtharaj Francis, Ali N. Chamseddine, Rania Faouzi Zaarour, Hassan Venkatesh Goutham, Salem Chouaib, Stéphanie Buart, Raefa Abou Khouzam
Publikováno v:
Seminars in Cancer Biology
Seminars in Cancer Biology, Elsevier, 2020, 65, pp.140-154. ⟨10.1016/j.semcancer.2020.01.003⟩
Seminars in Cancer Biology, Elsevier, 2020, 65, pp.140-154. ⟨10.1016/j.semcancer.2020.01.003⟩
Immunotherapy is poised to become an increasingly utilized therapy in the treatment of cancer. However, several abnormalities in the tumor microenvironment (TME) that can thwart the efficacy of immunotherapies have been established. Microenvironmenta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37758d2d0f11000f5b3838821d16f62d
https://hal.archives-ouvertes.fr/hal-03491350
https://hal.archives-ouvertes.fr/hal-03491350